Cargando…

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

BACKGROUND: We evaluated the efficacy of adjuvant durvalumab after neoadjuvant concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: This randomized, double-blind, phase II study included patients with ESCC who underwent curative surger...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, S., Sun, J.-M., Choi, Y.-L., Oh, D., Kim, H.K., Lee, T., Chi, S.A., Lee, S.-H., Choi, Y.S., Jung, S.-H., Ahn, M.-J., Ahn, Y.C., Park, K., Shim, Y.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850741/ https://www.ncbi.nlm.nih.gov/pubmed/35158205 http://dx.doi.org/10.1016/j.esmoop.2022.100385

Ejemplares similares

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
por: Park, Seong Yong, et al.
Publicado: (2023)

Combined effects of sous-vide cooking conditions on meat and sensory quality characteristics of chicken breast meat
por: Park, C.H., et al.
Publicado: (2020)

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
por: Shin, Sumin, et al.
Publicado: (2020)

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?
por: Chong, Yousun, et al.
Publicado: (2014)

Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view
por: Lim, D H, et al.
Publicado: (2004)

A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management
por: Lee, H-S, et al.
Publicado: (2007)

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2022)

Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report.
por: Kim, S. B., et al.
Publicado: (1995)

Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy
por: Yoshikawa, R, et al.
Publicado: (2008)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
por: Pantarotto, Marcos, et al.
Publicado: (2023)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
por: Cho, Won Kyung, et al.
Publicado: (2016)

Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
por: Yoon, Han Gyul, et al.
Publicado: (2020)

Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
por: Kim, Yong-Hyub, et al.
Publicado: (2015)

Selection of Adjuvant Treatment Without Neoadjuvant Chemoradiotherapy for Patients With Rectal Cancer: Room for Further Investigation
por: Park, In Ja
Publicado: (2018)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
por: Senan, S., et al.
Publicado: (2022)

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes
por: Samuels, Stuart E., et al.
Publicado: (2017)

Therapeutic embolization of the dural arteriovenous malformation involving the jugular bulb.
por: Park, J. Y., et al.
Publicado: (2001)

Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
por: Cho, E.H., et al.
Publicado: (2021)

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
por: Lee, Dae Ho, et al.
Publicado: (2023)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Clinical significance of microvessel density in multiple myeloma patients.
por: Ahn, M. J., et al.
Publicado: (2001)

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
por: Mayadev, Jyoti, et al.
Publicado: (2020)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021)

Clinical influence of neoadjuvant chemoradiotherapy on immunonutritional status in locally advanced rectal cancer
por: Lee, Soohyeon, et al.
Publicado: (2023)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Yap, Wing-Keen, et al.
Publicado: (2022)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Yun, Jae Kwang, et al.
Publicado: (2022)

Durvalumab: A Review in Advanced Biliary Tract Cancer
por: Fung, Simon, et al.
Publicado: (2023)

Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer
por: Lee, Hyebin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g5b2tg6b1ohnvv3akaapqlh5bi